Four families are desperate to raise funds for paralyzing disease for children

Four American families are desperate to save their children from a devastating genetic disease. The cure exists, but it is up to them to raise $ 1.15 million to finance a clinical trial.

Each of these families has a child with spastic paraplegia 50 (SPG50), a rare neurological disorder that affects less than 100 people in the world.

In an interview in the camera with News Digital, families talked about their career against time to ensure treatment. (See the video at the top of the article).

Frantic mother to save a clinical trial that could cure her daughter: “The treatment is sitting in a refrigerator”

The objective of families is to raise $ 1.15 million at the end of October to begin trial in the United States, have established a non -profit organization called Jack corner To help with fundraising efforts.

What is SPG50?

SPG50 slows down Child developmentthat gradually, which leads to cognitive impairment, muscle weakness, speech deterioration and finally paralysis, according to the National Organization for Rare Disorders.

“The forecast varies from one person to another, but it is generally a progressive condition,” said Dr. Eve Elizabeth Penney, epidemiologist of the Department of Health Services of the Texas state and Drugwatch medical taxpayer, to News Digital.

“Children with SPG50 can experience early delays in development, muscle weakness and spasticity,” he continued. “Over time, symptoms can get worse, which makes it difficult for affected people to walk and perform daily activities.”

There is currently no treatment currently approved by the United States Food and Medicines Administration (FDA) for SPG50. However, one exists, thanks to Terry Pirovolakis, a father in Canada whose son was diagnosed in 2017.

The father created a drug to save his son from a rare disease, now other families are desperate to get it

“They told us that we simply go home and love him, and they said he would be paralyzed by the waist for the age of 10, and Tetipléjico at age 20,” Pirovolakis told News Digital about the diagnosis of his son. “They said he would never walk or speak, and that he would need support for the rest of his life.”

When refusing to accept this result, Pirovolakis embarked on a mission to save his son: he settled his savings, met with numerous experts and paid scientists to create a gene therapy.

In March 2022, his son received gene therapy and is now thriving. Pirovolakis then opened a phase 2 study in the United States, which treated three more children. Everyone has reported that the disease has stopped progressing and their cognition has improved.

Now, the objective is to move to a phase 3 essay, which would allow more children to be treated, but because the medicine is not yet approved by the FDA, families will need to raise the funds for the trial themselves.

Four families, a rare disease

Rebekah Lockard, from Littleton, Colorado, is desperate for treating his 4 -year -old girl, Naomi, who was diagnosed with SPG50 in 2023.

His youngest son, Jack, was also diagnosed with SPG50 and received therapy in a previous essay due to his younger age.

“Naomi is still unable to walk and has a wheelchair for mobility, while Jack moves quickly with the help of a walker,” Lockard told News Digital. “Naomi has some sounds and gestures he uses to communicate, while Jack navigates his gestures and his understanding of what we say.”

“Every day, we are very grateful that Jack has received significant treatment at an early age. And every day, we feel despair that we could not give Naomi the same quality of life.”

Mother with rare als promotes ‘miraculous drugs’ who has stopped her illness

Emma and Dylan Jobsis, from Juanau, Arkansas, have a 4 -year -old son, Cade, who was also diagnosed in 2023.

“At this time, Cade can still walk short distances with his walker, but without treatment, we know he will lose that ability,” Emma Jobsis told News Digital.

“There are eight doses, sit and wait for children to be given desperately.”

“At this time, we live with the daily fear of seeing our child to lose skills and independence that has worked so hard to win. Without treatment, the future of Cade is of decline, eventually losing the ability to walk, feed and do the things that they do who is who he is.”

Jordan and Cody Medeiros, from Scio, Oregon, were devastated to learn that their 4 -year -old son, Lincoln, has Spg50.

“From the diagnosis of Lincoln two years ago, Spg50 has slowly removed its ability to walk safely,” Jordan Medeiros told News Digital. “It falls often, several times a day. And you can’t verbalize your pain or frustrations.”

“The worst part is that there are eight doses, sitting and waiting to be given to children who need it desperately.”

Click here to get the News application

In Susquehanna, Pennsylvania, Jami and Cody Wood welcomed twins in 2022. In August 2025, they were devastated when they learned that one of the twins, Mila, had Spg50.

Only three weeks later, Mila took her first steps, a milestone that her parents described as “bittersweet.”

“Without the drug, we will be condemned to see her slowly escape.”

“We know that there is only a treatment available for her, and without it, she will lose that milestone in as long as she took her,” Jami Wood told News Digital.

“Gene therapy is currently the other treatment option for Mila, and this essay is our daughter’s only opportunity to stop the progression of this terrible disease. Without the medication, we will be condemned to look at her slowly.”

Looking to the future

The hope is that after a successful phase 3 trial, the medicine will obtain the approval of the FDA, which would mean that insurance companies and the government would cover this “great cost load,” Pirovolakis told News Digital.

Click here to register in our health newsletter

“More importantly, it will be in the newborn detection panel, so we will have the opportunity to catch and eradicate this disease.”

Pirovolakis and his team are actively working with the FDA to obtain the approval of this therapy, but “the process is anything but simple,” he said.

The challenge is that the FDA currently applies the same manufacturing standards to small programs such as Pirrovolakis, which can only serve a few children in the United States, as they do with diseases that affect hundreds of thousands of children.

“For large -scale conditions, economies of scale help reduce costs, but in our case, these requirements become almost impossible to meet,” said Pirovolakis. “We need FDA flexibility for these ultra rare conditions.”

For more health articles, visit www.Newsnews.com/health

Any person interested in learning more about SPG50 and families can visit the Jack corner website.

News Digital contacted the FDA to comment.